Bioconjugate companies develop technologies that chemically link biological molecules to drugs, imaging agents, polymers or other functional components. These approaches are used to improve targeting, stability, delivery and detection across therapeutics, diagnostics and life science research.
This category includes companies working on:
Browse 28 UK bioconjugate companies below.
Target discovery platform and antibody-based therapies for oncology
Oxford BioTherapeutics is an Oxford-based clinical-stage oncology company discovering and developing first-in-class antibody-based cancer therapies. Its proprietary platform…
Clinical-stage antibody-drug conjugate developer for cancer
Iksuda Therapeutics is a clinical-stage biotechnology company developing antibody-drug conjugates for difficult-to-treat solid and haematological cancers. Its ADC platform…
Antibody fragment drug conjugate platform for solid tumour oncology
Antikor Biopharma is a pre-clinical stage biotechnology company developing antibody fragment drug conjugates for the treatment of solid tumours. The company's proprietary platform…
Chemical reagents and contract manufacturing for pharma and diagnostics supply chains
Biosynth Limited is the UK manufacturing and research entity of Biosynth, a global life sciences reagents and contract development and manufacturing organisation. Its Compton,…
Glycan analysis products and services for biopharmaceutical QC
Ludger is a glycobiology company specialising in the measurement and characterisation of protein glycosylation for biopharmaceutical development and quality control. The company…
Tumour-activated peptide drug conjugates for targeted oncology
Avacta Therapeutics is a clinical-stage biotechnology company developing peptide drug conjugates designed to deliver toxic chemotherapy payloads selectively within the tumour…
Antibody-oligonucleotide conjugates for spatial biology and proteomics
AbOliGo is a biotechnology company developing antibody-oligonucleotide conjugates (AOCs) for multiplexed protein analysis, spatial biology and single-cell workflows. Its…
Complex molecule synthesis and chemistry-driven cancer drug discovery
New Path Molecular Research is a Cambridge-based chemistry company spun out from the laboratory of Professor Steve Ley at the University of Cambridge. The company specialises in…
Integrated drug discovery CRO from target to clinical candidate
Sygnature Discovery is a UK-headquartered integrated drug discovery contract research organisation. Operating from sites in Nottingham, Alderley Park, and Glasgow, the company…
Clinical-stage company developing radioligand cancer therapies
Blue Earth Therapeutics is a clinical-stage biotechnology company developing targeted radiopharmaceutical therapies for cancer. Its pipeline centres on prostate-specific membrane…
CDMO and CRO for complex biologics and bioconjugate development
Abzena is an integrated CDMO and CRO specialising in complex biologics and bioconjugates, with cGMP facilities across the United States and a research presence in Cambridge, UK.…
Contract antibody production, purification, and conjugation services
The Antibody Company is a contract research organisation specialising in the production, purification, and conjugation of monoclonal and polyclonal antibodies. The company serves…